Cynata Therapeutics Ltd
CYP
Company Profile
Business description
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.
Contact
100 Cubitt Street
Level 3
CremorneVIC3121
AUST: +61 370676940
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
2
Stocks News & Analysis
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
stocks
Major ASX miner remains overvalued following production update
Iron ore strength keeps production on track despite lower copper output.
stocks
Ahead of earnings, is Alphabet stock a buy, a sell, or fairly valued?
From Google Cloud to Gemini user retention, here’s what we expect from Alphabet’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.90 | 33.40 | 0.37% |
| CAC 40 | 8,345.51 | 5.40 | 0.06% |
| DAX 40 | 24,902.40 | 55.71 | 0.22% |
| Dow JONES (US) | 51,839.26 | 307.16 | -0.59% |
| FTSE 100 | 10,546.54 | 21.78 | 0.21% |
| HKSE | 25,132.29 | 10.76 | -0.04% |
| NASDAQ | 25,508.07 | 12.17 | -0.05% |
| Nikkei 225 | 66,232.19 | 2,091.07 | 3.26% |
| NZX 50 Index | 13,656.03 | 40.00 | -0.29% |
| S&P 500 | 7,443.28 | 14.41 | -0.19% |
| S&P/ASX 200 | 8,793.30 | 36.30 | 0.41% |
| SSE Composite Index | 3,864.37 | 68.09 | 1.79% |